Patient N	lame	Patient Name	Patient Name
DOE	3	DOB	DOB
5027	'50 U	502750	502750



7035 Bee Cave Rd/RM-224, Ste. 207 Austin, TX 78746 Tel: (858) 217-5918 Fax: (866) 789-9585 Lab Director: Nicholas Bevins, M.D., Ph.D. CLIA #45D2287536



 Customer Information					

MOLECULAR DIAGNOSTICS via PCR						
Last Name: DOB://						
East Name:	FIISUNAII	ne:		ust be 18 years or older)		
Date Collected:/	/ Time Collected	d· · ΔΛ	1 / PM Riological Sev	Пм П ғ		
Date Collected//	/ Time conected	u An	17 FW Biological Sex.			
Ordering Provider:		Attach patient demographi	cs w/insurance card	Uninsured Patient		
Diagnosis Code(s):*						
☐ Black/African-American ☐ Hist	panic/Latino/Spanish Origin	Asian	American Indian/Alaskan Native			
☐ Black/African-American ☐ Hispanic/Latino/Spanish Origin ☐ Asian ☐ White/Caucasian ☐ Native Hawaiian/Other Pacific Islander ☐ Other:						
☐ White/Caucasian ☐ Nat	ive Hawaiian/Other Pacific Islan	ider 🗀 Other:	L Refused			
* Documentation in the patient's medical recor	,,	3		al Coverage Determinations (LCDs)		
	ERING MULTIPLE PANELS, EAC	H PANEL WILL REQUIRE ITS				
URINARY TR BD Vacc	RACT INFECTION TESTS utainer C&S Tube (gray)	RESPIRATORY PA Respiratory and Viral Tran	THOGEN TESTS sport Medium (red top)			
Urinalysis UA Preservative Tube Red	quired		Respiratory Pathogen Menu			
Complete UTI Panel with Antibiotic	Resistance Menu w/ Sensit	tivity	Influenza A (incl. H1, H3, H5, and H7)			
			Influenza B (Yamagata and Victoria lineages)			
Urinary Tract Infection Menu	Antibiotic Resistance Menu		Respiratory Syncytial Virus (incl. type A and B)			
Acinetobacter baumannii	Beta-lactamase (blaKPC)		SARS-CoV2-2 a			
Candida albicans	Beta-lactamase (CTX-M-Group 1		SARS-CoV2-2 b			
Candida glabrata	Metallo-Beta-lactamase (blaNDI	M)				
Citrobacter freundii	Fluoroquinolones	CE	VIIALLY TO A NICHALT	ED INFECTION TECTS		
Enterobacter cloacae	Methicillin/Oxacillin (mecA)		BD Vacutainer C&S Tul	TED INFECTION TESTS be (gray) OR E-swabs		
Enterococcus spp.	Sulfonamides					
Escherichia coli Klebsiella pneumoniae	Trimethoprim		Complete STI Panel with Resi	stance Markers & Pathogenic Flora		
Morganella morganii	+		Chlamydia trachomatis	Mycoplasma hominis		
Proteus mirabilis	+		HSV-1 (Herpes-Simplex)	Neisseria gonorrhoeae		
Pseudomonas aeruginosa	+		HSV-2 (Herpes-Simplex)	☐ Trichomonas vaginalis		
Staphylococcus aureus	+		Mycoplasma genitalium	Ureaplasma urealyticum		
Staphylococcus saprophyticus						
Streptococcus agalactiae						
DACTEDIAL V	AGINOSIS PANEL E-Swabs		Group A St	reptococcus		
				vngeal Swab		
Complete Panel		tobacillus gasseri	nasopharyngear swao			
· Ca		tobacillus iners				
		tobacillus jensenii				
	3 —	homonas vaginalis	alis			
Candidi glabrata La	ctobacillus crispatus					
AUTHORIZATION/SIGNATUR	RES					
DONOR: I certify that the specimen and information	on provided is my own and has not been subs	stituted or adulterated. I further grant perm	ission for the testing of my specimen f	for the presence of drugs and/or alcohol.		

l authorize Birdrock Laboratories to share the information on this form and my test results with my designated insurance carrier if necessary for reimbursement, to appeal any reimbursement denial, and authorize all reimbursements to be paid directly to the laboratory in consideration of services performed. I acknowledge that Birdrock Laboratories may be outside my network of insurance and I may be responsible for the amount due as determined by said insurance. I authorize Birdrock Laboratories to release the results of this testing to the treating authorized healthcare provider or facility.

ORDERING PROVIDER: Medicare will only pay for tests that meet the Medicare coverage criteria and are reasonable and necessary to treat or diagnose an individual patient. Section 1862(a)(1)(A) of the Social Security Act states, "no payment may be made under Part A or Part B for any expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member." Tests submitted for Medicare reimbursement must meet program requirements or the claim may be denied. I certify that the above ordered tests are medically necessary for the diagnosis and treatment of this patient. I have documented this test in the patient's chart. I acknowledge that Medicare does not generally cover routine screening tests.

The patient understands and agrees that the patient's leftover specimen and clinical information may be used, without information directly identifying the patient, for research, education, and other business purposes of Birdrock Laboratories (each a "secondary uses" and together "secondary uses"). The patient understands that this may involve Birdrock Laboratories sharing the patient's leftover specimen and clinical information will be assigned a unique code before any secondary uses. The patient's name or other personal identifying information will not be used in or linked to the patient's specimen and clinical information when they are shared with third parties unless the patient explicitly authorizes that disclosure. Furthermore the leftover specimen will become the property of Birdrock Laboratories. The specimens could lead to discoveries or inventions that may be of value to Birdrock Laboratories or to other organizations. You do not have any right to money or other compensation stemming from products that may be developed from the specimens unless expressly required under applicable state law.

Donor Authorization Signature: Ordering Health Care Provider Signature (Required): Date (Reauired):

DIAGNOSIS (ICD-10) CODES

Commonly Used ICD-10 Diagnosis Codes

UA/UTI Codes

B30.9 - Vital conjunctivitis

B37.41 - Candidal cystitis and urethritis

B37.49 - Other urogenital candidiasis

M25.5X - Joint disorders (various)

N02.x - Recurrent and persistent hematuria

N30.1X - Interstitial cystitis (chronic)

N30.11 - Interstitial cystitis (chronic) with

hematuria

N30.2X - Other chronic cystitis

N34.1 - Nonspecific urethritis

N34.2 - Other urethritis

N39.0 - Urinary tract infection, site not

specified

N39.4X - Other specified urinary incontinence

N39.41 - Urge incontinence

N41.0 - Acute prostatitis

N41.8 - Other inflammatory diseases of

prostate

N76.0 - Acute vaginitis

O23.1X - Infections of bladder in pregnancy

O23.2X - Infections of urethra in pregnancy

O23.4X - Unspecified infection of urinary tract

in pregnancy

O23.9X - Other and unspecified

genitourinary tract infection in pregnancy

R10.30 - Lower abdominal pain, unspecified

R21 - Rash and other nonspecified skin conditions

R31.1 - Benign essential microscopic hematuria

R32 - Unspecified urinary incontinence

R33.X - Retention of urine

R35.0 - Frequency of micturition

R50.9 - Fever (unspecified)

Z03.89 - Observation for other suspected conditions

Z11.X - Encounter for screening for infections and

parasitic diseases

Z87.440 - Personal history of urinary

(tract) infections

Other: _____

Respiratory Codes

J02.9 - Acute Pharyngitis

J01.90 - Acute Sinusitus, Unspecified

J00 - Acute Nasopharyngitis

J43.2 - Centriacinar Emphysema (HCC)

J32.9 - Unspecified Sinusitus, Chronic

J43.9 - Emphysema, Unspecified

J44.9 - Asthma with chronic obstructive pulmonary disease (COPD) (HCC) J01.90

Acute Sinusitus, Unspecified

J03.90 - Acute Tonsillitis

J31.0 - Unspecified Rhinitis

J06.9 - Acute Upper Respiratory Infections of

Unspecified Site

J40 - Bronchitis, Unspecified

J44.9 - COPD

J43.2 - Emphysema, Centrilobular

R91.1 - Pulmonary Nodule, Solitary

R50.9 - Fever, unspecified

R05.X - Cough

R06.02 - Shortness of breath

Z11.59 - Encounter for screening for other

viral diseases

Z20.828 - Contact with (and suspected exposure

to) other viral communicable diseases

Other:

Testing performed by Birdrock Laboratories is compliant with all local and state guidelines and regulations. Any testing performed at our facility is based on current coding:

- CPT 87798 Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism.
- CPT 87640 Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique.
- CPT 87641 Staphylococcus aureus, methicillin resistant, amplified probe technique.
- CPT 87653 Infectious agent detection by nucleic acid (DNA or RNA); Streptococcus, group B, amplified probe technique.
- CPT 87481 Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique.
- CPT 87150 Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed.
- CPT 81002 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents.

All tests ordered for Medicare or Medicaid reimbursement must meet the program's requirements or the claim may be denied. Testing should **ONLY** be performed when it is considered medically necessary by a qualified healthcare professional.